Phase 2 trial of a DNA vaccine (pTVG-HP) and nivolumab in patients with castration-sensitive non-metastatic (M0) prostate cancer.
Journal Information
Full Title: J Immunother Cancer
Abbreviation: J Immunother Cancer
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
4/6
66.7% Transparent
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
Data Sharing
Code Sharing
COI Disclosure
Evidence found in paper:
"Competing interests: DGM has ownership interest, has received research support, and serves as consultant to Madison Vaccines, which has licensed material described in this manuscript and supported this trial. None of the other authors have relevant potential conflicts of interest."
Funding Disclosure
Evidence found in paper:
"Funding: Grant support was provided by NIH (P30 CA014520). Nivolumab was provided by Bristol Myers Squibb. pTVG-HP was provided by Madison Vaccines. The TRAQinform IQ bone imaging analysis was conducted by AIQ Solutions, and funded by Madison Vaccines."
Protocol Registration
Evidence found in paper:
"Trial registration number NCT03600350."
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025